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In vitro Lymphocyte Proliferative Responses and gamma-Interferon
Production as Measures of Cell-Mediated Immunity of Cattle Exposed to
Pasteurella haemolytica
Abstract
Cell-mediated immune mechanisms may play a role in the pathogenesis and prevention of pneumonia in
cattle caused by Pasteurella haemolytica serotype A1. To determine the circumstances required to stimulate
and identify cell-mediated immune responses, calves were vaccinated with a commercial P. haemolytica
bacterin or a live commercial P. haemolytica vaccine, or were infected intratracheally with virulent P.
haemolytica. All calves were challenge-exposed intratracheally with P. haemolytica 31 d after vaccination or
prior infection. Peripheral blood mononuclear cells and mediastinal and superficial cervical lymph node cells
were stimulated with antigens prepared from P. haemolytica to evaluate in vitro proliferative responses and
gamma-interferon production as measures of cell-mediated immunity. Strong proliferative responses and
gamma-interferon production were detected in lymph node cells from calves vaccinated with the live vaccine
and from infected calves, especially in response to stimulation with an outer membrane protein preparation
from P. haemolytica. Greater proliferative responses and gamma-interferon production were associated with
the lymph node nearer the site of bacterin administration (superficial cervical lymph node) or the site of
infection (mediastinal lymph node), whereas greater proliferative responses and gamma-interferon
production were associated with the more distant lymph node (mediastinal lymph node) in calves vaccinated
with the live vaccine. Neither proliferative responses nor gamma-interferon production were detected in
peripheral blood mononuclear cells from calves that were vaccinated for or infected with P. haemolytica.
Antileukotoxin antibody titers were determined by a serum neutralization assay, and protection against
pneumonic lesions was more closely correlated with antileukotoxin antibody responses than with lymphocyte
proliferation or gamma-interferon responses.
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In vitro Lymphocyte Proliferative Responses and 'Y-Interferon 
Production as Measures of Cell-Mediated Immunity of Cattle 
Exposed to Pasteurella haemolytica 
Brad M. DeBey, James A. Roth, Kim A. Brogden, Randall C. Cutlip, Mark G. Stevens, Ted Jones, Robert E. Briggs, 
and John P. Kluge 
ABSTRACT 
Cell-mediated immune mecha-
nisms may play a role in the patho-
genesis and prevention of pneumo-
nia in cattle caused by Pasteurella 
haemolytica serotype Al. To deter-
mine the circumstances required to 
stimulate and identify cell-mediated 
immune responses, calves were vac-
cinated with a commercial P. hae-
molytica bacterin or a live commer-
cial P. haemolytica vaccine, or were 
infected intratracheally with viru-
lent P. haemolytica. All calves were 
challenge-exposed intratracheally 
with P. haemolytica 31 dafter vacci-
nation or prior infection. Periph-
eral blood mononuclear cells and 
mediastinal and superficial cervical 
lymph node cells were stimulated 
with antigens prepared from P. hae-
molytica to evaluate in vitro prolif-
erative responses and -y-interferon 
production as measures of cell-
mediated immunity. Strong prolif-
erative responses and -y-interferon 
production were detected in lymph 
node cells from calves vaccinated 
with the live vaccine and from 
infected calves, especially in 
response to stimulation with an 
outer membrane protein prepara-
tion from P. haemolytica. Greater 
proliferative responses and -y-inter-
feron production were associated 
with the lymph node nearer the site 
of bacterin administration (superfi-
cial cervical lymph node) or the site 
of infection (mediastinal lymph 
node), whereas greater proliferative 
responses and -y-interferon produc-
tion were associated with the more 
distant lymph node (mediastinal 
lymph node) in calves vaccinated 
with the live vaccine. Neither prolif-
erative responses nor -y- interferon 
production were detected in perip-
heral blood mononuclear cells from 
calves that were vaccinated for or 
infected with P. haemolytica. Anti-
leukotoxin antibody titers were 
determined by a serum neutraliza-
tion assay, and protection against 
pneumonic lesions was more closely 
correlated with antileukotoxin anti-
body responses than with lympho-
cyte proliferation or -y-interferon 
responses. 
RESUME 
L'immunite a mediation cellu-
laire pourrait avoir un role a jouer 
dans Ia pathogenese et Ia prevention 
de Ia pneumonie a Pasteurella 
haemolytica serotype A1 chez les 
bovins. Afin de determiner les fac-
teurs requis pour stimuler et identi-
fier Ia reponse immunitaire a media-
tion cellulaire, des veaux ont ete 
vaccines avec one bacterine com-
merciale de P. haemolytica ou un 
vaccin vivant commercial de P. 
haemolytica, ou ont ete infectes par 
voie intra-tracheale avec one 
souche virulente de P. haemolytica. 
Tous les veaux furent inocules par 
voie intra-tracheale avec P. hae-
molytica 31 jours apres Ia vaccina-
tion ou Ia premiere infection. Des 
cellules mononucleees du sang 
peripherique et des cellules des 
noeuds lymphatiques mediastinaux 
et cervicaux superficiels furent 
stimulees avec des antigenes pre-
pares a partir de P. haemolytica 
dans le but d'evaluer les reponses 
proliferatives in vitro et Ia produc-
tion d 'interferon--y, deux mesures 
de l'immunite cellulaire. De fortes 
reponses proliferatives et one pro-
duction elevee d'interferon--y furent 
detectees dans les cellules des 
noeuds lymphatiques des veaux vac-
cines avec le vaccin vivant et ceux 
des veaux pre-infectes, en reponse a 
one stimulation avec one prepara-
tion d 'one proteine de Ia membrane 
externe de P. haemolytica. Les 
reponses proliferatives et Ia produc-
tion d 'intereron--y etaient plus 
fortes dans le noeud lymphatique le 
plus pres du site d'administration 
de Ia bacterine (noeud lymphatique 
cervical superficiel) ou du site 
d'infection (noeud lymphatique 
mediastinal), alors que les reponses 
proliferatives et Ia production 
d'interferon--y les plus fortes etaient 
observees dans le noeud lympha-
tique le plus eloigne (noeud lympha-
tique mediastinal) chez les veaux 
vaccines avec le vaccin vivant. 
Aucune reponse proliferative ni 
production d'interferon--y ne furent 
detectees dans les cellules mononu-
clees du sang peripherique chez les 
veaux vaccines contre ou infectes 
avec P. haemolytica. Les titres 
d'anticorps anti-leucotoxine furent 
determines par one epreuve de 
seroneutralisation, et Ia protection 
contre les lesions de pneumonie 
etait plus en correlation avec le titre 
d'anticorps anti-leucotoxine qu'avec 
Ia proliferation lymphocytaire ou Ia 
production d'interferon--y. 
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INTRODUCTION 
Pasteurella haemolytica biotype A 
serotype 1 causes severe pneumonia 
in cattle. Experimental and commer-
cial vaccines, including killed bac-
terins and live vaccines have been 
developed for immunization of cattle 
against P. haemolytica. In earlier 
reports, immunization with P. hae-
molytica bacterins provided poor pro-
tection of cattle against natural or 
experimental disease (1-3), and has 
even been associated with enhance-
ment of experimental and natural dis-
ease (4,5). Immunization of calves 
with bacterins in Freund's adjuvant 
(6), or live P. haemolytica (7-10), 
however has been demonstrated to 
provide protection against challenge. 
Pasteurella haemolytica produces a 
potent leukotoxin that is inhibitory or 
lethal to bovine neutrophils, mononu-
clear phagocytes, and lymphocytes 
(11-13). Investigators have attributed 
the protection afforded by live vac-
cines to their induction of leukotoxin-
neutralizing antibodies (14). Calves 
protected against P. haemolytica chal-
lenge by immunization with a bacterin 
in Freund's adjuvant, however, did 
not produce leukotoxin-neutralizing 
antibodies, indicating that aspects of 
the immune response other than 
antileukotoxin antibody can afford 
protection (6). Subsequently, it was 
demonstrated that immunization of 
calves with a commercial P. hae-
molytica culture supernatant vaccine 
(Presponse, Langford, Guelph, Ont-
ario) containing leukotoxin and other 
soluble antigens protected against 
experimental infection (15), while 
recombinant P. haemolytica leuko-
toxin did not result in protective 
immunity (16), also supporting that 
effective humoral immune protection 
probably requires antibody responses 
to somatic antigens of P. haemolytica 
in addition to antileukotoxin antibod-
ies. Others (9, 17) have suggested that 
cell-mediated immune (CMI) 
responses may play a role in immu-
nity to P. haemolytica-induced pneu-
monia. The authors of the present 
study were unable to find reports of 
attempts to measure CMI to P. hae-
molytica antigens in cattle after vacci-
nation or recovery from infection. 
The purpose of this study was to 
measure aspects of CMI responses of 
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cattle to P. haemolytica, as well as 
identify P. haemolytica antigens that 
can be used to measure this response. 
Calves infected with P. haemolytica 
and calves vaccinated with a live or 
killed P. haemolytica vaccine were 
used to evaluate CMI responses to P. 
haemolytica. Peripheral blood mono-
nuclear cells (PBMC) and lymph node 
cells were harvested and stimulated 
with 5 antigen preparations from 
P. haemolytica. Lymphocyte prolifera-
tive responses and 'Y-interferon produc-
tion were used as measures of CMI. 
To asses the role of CMI versus 
humoral immunity as protective fac-
tors against pneumonic pasteurellosis, 
all calves were challenge-exposed to 
P. haemolytica, and lung lesions and 
bacterial concentrations in lung tissues 
were assessed for correlation with 
lymphocyte proliferative responses, 
'Y-interferon production, and anti-
leukotoxin antibodies. 
MATERIALS AND METHODS 
BACTERIAL CULTURE 
Pasteurella haemolytica biotype A 
serotype 1 (strain Ll01, kindly pro-
vided by G.H. Frank, Ames, Iowa) was 
isolated on blood agar from a pneu-
monic bovine lung. Tryptose broth cul-
tures were incubated at 37°C for 6 h, 
dispensed into vials in 1 mL aliquots, 
and stored at -70°C until used for 
antigen or inoculum preparations. 
ANTIGEN PREPARATION 
Capsular polysaccharide (CP), 
lipopolysaccharide (LPS), lipopoly-
saccharide-associated protein (LAP), 
and a bacterial cell sonicate (SON) 
were prepared from P. haemolytica 
strain L101 for use as antigens to 
stimulate PBMC and lymph node cell 
cultures. An outer membrane protein 
preparation (OMP) of P. haemolytica 
serotype 1 was kindly provided by 
A.W. Confer, Stillwater, Oklahoma, 
prepared as previously described (18). 
Strain L101 was grown on dextrose 
starch agar for 24 h at 37°C, and har-
vested in distilled water. Bacteria 
were pelleted by centrifugation and 
the supernatant was saved. Cells were 
dehydrated in 50% ethanol, washed 
twice in acetone, twice in ethyl ether, 
and then air-dried. 
The supernatant was placed in dial-
ysis bags (12-14, 500 nominal mol. 
wt. cutoff, Spectrum Medical Indus-
tries, Los Angeles, California) and 
covered with carboxymethylcellulose 
(Aquacide I, Calbiochem Corp, 
La Jolla, California). The CP was 
extracted from the concentrated cul-
ture supernatant as previously 
described (19). Alpha-amylase (Sigma 
Chemical Co, St. Louis, Missouri) was 
added to the extracted CP and the 
mixture was incubated for 2 h at 37°C 
and 18 h at 4 °C to remove residual 
starch from the growth medium. The 
CP was resuspended in a buffer 
(pH 7 .2) containing I 0 Mm Tris, 
145 Mm NaCI, 0.2% SDS and 500 ._.,g 
(16 U)/mL proteinase K (Amresco, 
Solon, Ohio). The suspension was 
heated at 60°C for 2 h then 18 h at 
37°C. The suspension was recycled 
for I h over an endotoxin-removing 
affinity column (Detoxi-gel, Pierce, 
Rockford, Illinois). The CP contained 
less than 0.25% protein (20) and 
0.01% LPS, as determined by a chro-
mogenic limulus amebocyte assay 
(QCL-1 000, Whittaker Bioproducts, 
Walkersville, Maryland). 
Lipopolysaccharide was extracted 
from dried cells with a phenol, chlo-
roform, and petroleum ether solution, 
as previously described (21). The LPS 
was treated with proteinase K simi-
larly as the CP, after which it con-
tained 0.7% protein (20). 
Lipopolysaccharide-associated pro-
tein was extracted from the phenol 
supernatant of the LPS extraction as 
previously described (22). The LAP 
contained 0.02% LPS. 
The SON was prepared by collect-
ing P. haemolytica cells from 18 h of 
growth on sheep blood agar plates 
that were incubated at 37°C. Cells 
were collected in distilled water and 
sonicated on ice with an ultrasonic 
cell disrupter (Microson, Heat Systems 
Ultrasonics, Farmingdale, New York) 
for 1 min at the maximum power set-
ting. The preparation was centrifuged 
at 5900 X g for 20 min, and the super-
natant was filtered through a 0.22 ._.,m 
filter. 
After extraction procedures, the 
CP, LPS, LAP and SON antigens 
were lyophilized. Prior to use, these 
antigens were resuspended in Hanks 
balanced salt solution in concentrations 
based on dry weight of the antigen 
preparation. The OMP antigen was 
resuspended based on 1-1g of 
protein/ J.Ll. 
CALVES 
Twelve colostrum-deprived, male 
Holstein and Holstein crossbred 
calves were obtained at birth and 
housed in isolation barns in American 
Association for Accreditation of Lab-
oratory Animal Care (AAALAC) 
accredited facilities. Calves were fed 
a complete pelleted ration twice daily, 
and water was available ad libitum. 
The calves were 3-7 mo old when 
used in the experiment. 
VACCINATION AND INFECTION OF 
CALVES 
Calves were divided into 4 groups 
of 3 calves, and were vaccinated or 
infected with P. haemolytica on day 0. 
Calves of one group (bacterin group) 
were vaccinated with a Pasteurella 
haemolytica-Pasteurella multocida 
bacterin (Pasteurella haemolytica-
Pasteurella multocida bacterin, Lot 
No. 923, Colorado Serum Co., Denver, 
Colorado). Calves in a 2nd group (live 
vaccine group) were vaccinated with a 
live P. haemolytica vaccine (Respir-
vac, Lot No. 7671, Beecham Labora-
tories, Bristol, Tennessee). Vaccines 
were administered in the subcutis of 
the left cervical area. Calves in a 3rd 
group (convalescent group) were 
intratracheally infected with 10 mL of 
an inoculum containing 3.0 X 108 
CFU of P. haemolytica strain L 101. 
The inoculum was prepared by inocu-
lating one aliquot of strain LlOl into 
30 mL of tryptose broth and incubat-
ing at 37°C for 3 h. Bacteria were pel-
leted by centrifugation at 5900 X g 
for 5 min, resuspended in tryptose 
broth to 80% transmittance at 600 nm 
wavelength, then further diluted in 
tryptose broth to approximately 1 X 108 
CFU/mL for inoculation of calves. 
Bacterial concentration was verified 
by plate counts. Calves in the conva-
lescent group were treated with gen-
tamicin (Gentocin, Schering Corp, 
Kenilworth, New Jersey) and ceftio-
fur (Naxcel, Upjohn Co, Kalamazoo, 
Missouri) on days 3-6 to reduce the 
morbidity following infection with 
P. haemolytica. A 4th group (unvacci-
nated group) consisted of calves that 
received no exposure to P. haemolyt-
ica. Body temperatures of all calves 
were monitored daily for 3 dafter ini-
tial vaccination or infection. Calves in 
the bacterin group were revaccinated 
on day 15 of the experiment. 
ANTILEUKOTOXIN ANTIBODY TITERS 
Serum samples were collected from 
all calves on days 1, 4, 8, 11, 15, 18, 
22, and 25 for determination of 
antileukotoxin antibody titers to 
P. haemolytica, using a serum leuko-
toxin neutralization assay (23) with 
minor modifications. BL-3 bovine 
lymphoma cells were used as target 
cells, and 100 1-11 of dimethylsulfoxide 
was added to each well just prior to 
the measurement of optical density at 
a dual wavelength (550-650 nm). 
Antileukotoxin titers were determined 
at the serum dilution where 30-70% 
of the BL-3 cells were killed. For 
standards, 100% of cells killed was 
determined by adding sonicated BL-3 
cells to wells, and 0% of cells killed 
was determined by including no toxin 
in the wells. Positive control wells on 
each plate, contained toxin added to 
cells in the absence of serum. Titers 
were converted to log2 prior to statis-
tical analyses. 
LYMPHOCYTE PROLIFERATION ASSAYS 
Blood was collected from calves on 
days 1, 4, 11, 15, 18, 22, and 25 for 
isolation of PBMC for lymphocyte 
proliferation assays. Fifty mL of 
venous blood were collected into 5 mL 
of acid citrate dextrose, centrifuged at 
600 X g for 25 min, and buffy coats 
were collected. Erythrocytes in buffy 
coats were lysed with phosphate 
buffered water, followed by restora-
tion of osmolarity with hypertonic 
phosphate buffered saline. Peripheral 
blood mononuclear cells were washed 
twice and resuspended in complete 
medium composed of RPMI 1640 
(Gibco Laboratories, Long Island, 
New York) supplemented with 25 Mm 
L-glutamine, 5 X I0-5 M 2-mercap-
toethanol, 10% bovine fetal serum, 
and 200 IU penicillin, 200 J.Lg strepto-
mycin and 0.5 1-1g amphotericin B/mL. 
Two-hundred 1-11 of complete medium 
containing 2 X 105 PBMC were deliv-
ered to each well of flat-bottom 
microtiter plates. Antigens (CP, LPS, 
LAP, and OMP), in 25 J.Ll of RPMI, 
were added to wells in triplicate at 
concentrations of 1.0 and 0.1 J.Lg/well. 
The SON antigen was added at 0.1 
and 0.01 J.Lg/well. Cell cultures were 
incubated for 52-54 h at 37°C in a 
humidified atmosphere with 5% C02, 
and pulse-labelled with W-thymidine 
(Amersham Corp, Arlington Heights, 
Illinois) at 0.4 J.LCi/well. Antigen con-
centrations and incubation periods 
were based on preliminary studies. 
Cells were incubated an additional 
18-20 h, harvested onto fiberglass 
filters, and radioactivity was mea-
sured by liquid scintillation counting. 
Mean counts per minute from antigen-
stimulated wells were divided by the 
mean counts per minute of the back-
ground wells (no antigen) and the 
quotient was designated as the stimu-
lation index (SI). 
For lymph node cell assays, lymph 
nodes (collected on days 35 or 36) were 
minced and cells were passed through 
#60 mesh stainless steel screens. Lym-
phocytes were isolated using 
Histopaque 1083 (Sigma Chemical 
Co), washed twice in 0.1 M phosphate-
buffered saline, pH 7 .2, and resus-
pended at 2 X 105 cells/mL in complete 
media. Lymph node cell preparations 
were thereafter treated in the same 
manner as PBMC preparations. 
'Y-INTERFERON ASSAYS 
Peripheral blood mononuclear cell 
and lymph node cell suspensions were 
added to plates and stimulated with 
antigens in the identical manner as 
that used for the lymphocyte prolifera-
tion assays. After 46-48 h incubation, 
plates were centrifuged at I 00 X g for 
5 min, and supernatants were col-
lected and immediately frozen and 
stored at - 20°C. 
'Y-interferon was measured using a 
commercial ELISA kit (Mycobac-
terium paratuberculosis gamma-
interferon test kit, IDEXX Laborato-
ries, Westbrook, Maine), with 
modifications. Culture supernatants 
were substituted for plasma samples, 
and bovine recombinant 'Y-interferon 
(IDEXX Laboratories) was used as a 
standard for quantitative determina-
tions. Supernatants from PBMC cul-
tures from days 4, 11, and 18 that 
were stimulated with OMP at 0.1 
J.Lg/well and supernatants from lymph 
node cell cultures that were stimu-
lated with OMP at 0.1 J.Lg/well were 
analyzed for 'Y-interferon. 'Y-inter-
feron concentrations in supernatants 
of background wells were subtracted 
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Figure 1. Mean serum antileukotoxin antibody titers of calves by experimental group as 
determined by a toxin neutralization assay. Calves were vaccinated or infected with P. 
haemolytica on day 0, and calves in the bacterin group were revaccinated on day 15. 
from those of supernatants of antigen-
stimulated wells and the difference 
was designated IFN. 
CHALLENGE AND NECROPSY 
On day 31 of the experiment, all 12 
calves were challenge-exposed intra-
tracheally to 10 mL of inoculum 
containing 2.0 X 108 CFU of P. 
haemolytica strain L1 01. Body tem-
peratures were monitored daily for 3 d 
after the challenge. Calves were euth-
anized and necropsied on days 35 (6 
calves) and 36 (5 calves). One calf 
from the unvaccinated group died on 
day 33 with severe pneumonic lesions 
as a result of the challenge. 
The caudal mediastinal and superfi-
cial cervical lymph node (ipsilateral 
to site of vaccination) were removed 
at necropsy for lymph node cell 
preparations in the lymphocyte prolif-
eration and 'Y-interferon assays. The 
volume of acute pneumonic paren-
chyma was estimated by visual obser-
vation and palpation for each calf and 
recorded as % pneumonia. Approxi-
mately 10 gm of pneumonic lung was 
collected from each animal for quanti-
tative bacterial culture, and the CFU 
of P. haemolyticalg of lung were con-
verted to log10 prior to statistical anal-
yses. The lung section was collected 
from a severely pneumonic area, or 
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from the right middle lobe if pneumo-
nia was not present. 
STATISTICAL ANALYSES 
Analysis of variance (SAS Institute 
Inc, Cary, North Carolina) was used 
to determine significant differences 
between groups for IFN, body temper-
ature, % pneumonia, and CFU of P. 
haemolyticalg of lung. Separate anal-
yses were performed for each combi-
nation of antigen, concentration, and 
lymph node location. When the over-
all F test was significant (P :::;; 0.05), 
t-tests (LSD) were used to determine 
specific differences between groups 
(P:::;; 0.05). 
For proliferative assay results, 
exploratory analysis indicated that the 
best measure of activity for statistical 
purposes was the logarithm of SI, 
which is biologically interpretable as 
a measure of the difference in rates of 
mitotic activity between stimulated 
and background wells. Each antigen's 
log-transformed SI were analyzed in a 
single mixed linear model (SAS proc 
mixed) using random effect terms as 
appropriate to specify a covariance 
structure compatible with the repeated 
measurements on animals (two lymph 
nodes per animal) and lymph nodes 
within animals (two antigen concen-
trations per node). Experiment wise 
significance levels for comparisons 
between groups were controlled by 
the stagewise modified Bonferroni 
procedure of Hommel (24), using log-
ical relations between hypothesis. 
Linear regression analysis was used 
to correlate immune responses (serum 
antileukotoxin antibody titer on day 
25, IFN and SI (from mediastinal 
lymph node cells stimulated with 
OMP at 0.1 J.Lg/well) to the severity of 
pulmonary disease (% pneumonia) 
(Fig. 4). Correlation coefficients were 
also determined for IFN versus SI 
(from mediastinal lymph node cells 
stimulated with OMP at 0.1 J.Lg/well) 
to correlate 'Y-interferon responses 
with proliferative responses. In addi-
tion, SI and IFN from mediastinal 
lymph node cells stimulated with 
OMP at 0.1 J.Lg/well were correlated 
with serum antibody response on day 
25 to determine relationships between 
CMI and the humoral immune 
response to leukotoxin. 
RESULTS 
CLINICAL RESPONSES OF CAL YES 
By 20 h after vaccination or initial 
infection, calves in the live vaccine 
and convalescent group had signifi-
cantly elevated body temperatures 
(P :::;; 0.05) compared to calves in the 
unvaccinated group. Body tempera-
tures in these two groups remained 
significantly elevated until approxi-
mately 96 h after vaccination or initial 
infection (data not shown). All 3 cal-
ves in the live vaccine group devel-
oped extensive swelling at the site of 
vaccination, which extended ventrally 
to the sternum in one calf. 
Calves in the convalescent group 
had clinical evidence of pneumonia 
after initial infection on day 0, which 
included hyperpnea, anorexia, and 
coughing. However, signs subsided 
by day 5. 
ANTILEUKOTOXIN ANTIBODY 
RESPONSES 
Serum antileukotoxin antibody 
titers peaked for the live vaccine and 
convalescent group on day 15 (Fig. 1). 
Calves in the bacterin group, which 
were revaccinated on day 15, had a 
maximum mean antibody titer on day 
25. After vaccination, calves in the 
bacterin and live vaccine group had 
similar antibody titers, while the 
calves in the convalescent group had 
much higher antileukotoxin titers . 
PROLIFERATIVE RESPONSES 
Fixed effects considered for inclu-
sion in the analysis of log SI included 
treatment group, node location, anti-
gen concentration, and the possible 
interactions of subsets of these main 
effects. In the case of CP, there was 
no strong evidence of differences 
between groups or node locations, and 
in fact the antigen appeared to be 
ineffective in stimulating activity 
above background levels. 
In the case of LPS, LAP, OMP, 
and SON, antigen concentration was 
not observed to interact with the 
other 2 main effects. The main effect 
of concentration was signficant only 
in the case of LAP and OMP; in both 
cases greater activity was observed at 
the higher concentration. Concentra-
tion was retained as a covariate in all 
4 analyses to reduce possible con-
founding, even when not achieving 
signficance. 
For all antigens except CP, evi -
dence for the presence of interaction 
between treatment and node location 
was strong (P values ranged from 
0.0007 to 0.011 ). This statistical 
interaction corresponds to the biologi-
cal observation that the relationship 
between the 2 node locations is differ-
ent in different treatment groups . As 
Figure 2 shows, which is typical for 
all antigens excluding CP, greater 
proliferative activity was observed in 
the superficial cervical lymph node 
cells in the control and bacterin 
groups, while the reverse was true in 
the live vaccine and convalescent 
groups . 
For each antigen, statistical tests 
were performed comparing mean log 
SI between lymph node locations in 
each treatment group, and between 
treatment groups at each node loca-
tion. In addition, the difference in log 
SI between the 2 lymph node loca-
tions was computed for each treat-
ment group and between-group com-
parisons of the differences were 
performed. To avoid spurious find-
ings of apparently significant results 
due merely to the large number of sta-
tistical tests conducted rather than to 
real differences in the quantities being 
compared, Hommel's modified Bon-
ferroni procedure was used to insure 
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Figure 2. Proliferative responses of superficial cervical and mediastinal lymph node cells 
stimulated with outer membrane protein (OMP) from P. llllemolytica. Calves were vaccinated 
or infected with P. llllemolytica 35 or 36 d prior to stimulation of lymph node cells. Values 
shown correspond to estimated mean log stimulation index (SI) by experimental group, con-
verted back to the SI scale by taking antilogarithms. Error bars correspond in the same way 
to values one standard error above estimated log SI. 
that in the absence of any differences, 
the probability of rejecting none of 
the hypotheses tested would be at 
least 0.95 . In our data, the procedure 
required an individual comparison to 
achieve approximately P < 0.003 to 
be declared significant. Under this 
stringent standard, the difference in 
mean log SI between superficial cer-
vical and mediastinal node cells was 
found to be unequal between the bac-
terin and convalescent treatment 
groups for all antigens except CP. In 
the case of LAP, the same statement 
can be made regarding the control and 
convalescent groups. 
Log SI was found to differ between 
the 2 lymph node locations in the bac-
terin group (for LPS and LAP) and in 
the convalescent group (for SON) . 
For OMP, log SI of mediastinal lymph 
node cells was higher for the conva-
lescent group than for the bacterin 
group. 
A large number of comparisons 
achieved individual P values that were 
less than 0.05, but not small enough 
for hypothesis rejection under the 
modified Bonferroni procedure . 
Because of the likelihood that some of 
these are statistical type I errors, they 
cannot be regarded as individually 
reliable. As a group, however, they are 
consistent with the results already pre-
sented, in that they suggest that: ( 1) in 
the convalescent and bacterin groups, 
proliferative activity levels differed 
between superficial cervical node cells 
and mediastinal node cells; (2) in the 
bacterin group, superficial cervical 
lymph node cells had higher prolifera-
tive responses than mediastinal cells, 
while the reverse was true in the con-
valescent group; and (3) mediastinal 
lymph node cells had higher prolifera-
tive responses in the convalescent 
group than in the bacterin group. 
Results for the control and live vac-
cine groups are less clear. There is no 
real evidence that the results observed 
in the control group differ from those 
in the bacterin group, but because of 
the loss of one control animal, the 
sample sizes in the control group are 
smaller, and statistical power is 
reduced. In the live vaccine group, the 
observed results are intermediate 
between the patterns exhibited in the 
bacterin and convalescent groups, and 
we are unable to make statistical dis-
tinctions in this study. 
Proliferative responses for PBMC 
stimulated with CP, LPS, LAP, OMP 
and SON were unremarkable when 
compared to background wells, with 
CPM generally below 2 X 103 CPM. 
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Figure 3. "(·interferon responses of superficial cervical and me~iastinal lymph nod~ cells 
stimulated with outer membrane protein (OMP) from P. haemolytrca. Calves were vaccmated 
or infected with P. haemolytica 35 or 36 ds prior to stimulation of lymph node cells. Values 
represent mean IFN (difference of nglmL of "(·interferon in antigen-stimula~ed wells from 
background wells) by experimental group. Means within a lymph node lackmg a common 
superscript differ (P !'> 0.05). Error bars indicate SEM. 
'Y·INTERFERON RESPONSES 
Differences between experimental 
groups in -y-interferon production in 
culture supematnants from mediastinal 
lymph node cells stimulated with OMP 
were present (P s; 0.002) (Fig. 3). The 
highest -y-interferon production 
occurred in the live vaccine group, 
which was significantly higher than the 
-y-interferon production of lympho-
cytes from the unvaccinated, bacterin 
or convalescent groups. -y-interferon 
production for the convalescent group 
was also significantly higher than the 
-y-interferon production of either the 
unvaccinated or bacterin groups. 
Significant differences between 
experimental groups were not present 
for -y-interferon production by super-
ficial cervical lymph node cells stimu-
lated with OMP (Fig. 3). Significant 
differences between experimental 
groups were not present for -y-inter-
feron of culture supernantants from 
PBMC stimulated with OMP for any 
of the days analyzed (Days 11, 18, 
and 25) (P > 0.05) (data not shown). 
NECROPSY FINDINGS 
Acute pneumonic lesions consisted 
of consolidated parenchyma of ventral 
portions of the lobes, often accompa-
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nied by hemorrhage and fibrinous 
pleuritis. The mean % pneumonia for 
each group was: unvaccinated- 25.1, 
bacterin- 10.5, live vaccine- 16.5, 
and convalescent - 0.1 (SEM = 9.6), 
with no significant differences 
between the experimental groups (P > 
0.05) due to the small number of ani-
mals in each group and the variability 
between animals within groups. 
Chronic lung lesions were present 
in two calves of the convalescent 
group, characterized by abscessation 
of ventral portions of all lung lobes. 
These lesions were consistent with 
pneumonia of several weeks duration, 
as a result of infection of the calves 
with P. haemolytica on day 0. 
Bacterial cultures of lungs revealed 
pure populations of P. haemolytica. 
Mean CFU logu/gm of lung by exper-
imental group were: unvaccinated 
group- 4.9, bacterin group - 5.0, 
live vaccine group - 7 .6, and conva-
lescent group - 5.8 (SEM = 1.6). 
There were no significant differences 
(P > 0.05) between the means. 
CORRELATIONS 
Lymphocyte proliferation and -y-
interferon production by OMP-stimu-
lated mediastinal lymph node cells 
were not significantly correlated with 
% pneumonia (Fig. 4A, B) or with 
bacterial concentration in pneumonic 
lesions. Serum antileukotoxin anti-
body titer on day 25 and % pneumo-
nia were significantly correlated (r = 
-0.75; P = 0.01) (Fig. 4C). 
The log SI of OMP-stimulated 
mediastinal lymph node cells (on day 
35 or 36) was significantly correlated 
with the antileukotoxin antibody titer 
on day 25, (r = 0.61; P = 0.05), how-
ever the -y-interferon production by 
OMP-stimulated mediastinal lymph 
node cells did not correlate signifi-
cantly with antileukotoxin antibody 
titer on day 25 (data not shown). -y-
interferon production by OMP-stimu-
lated mediastinal lymph node cells 
did not correlate significantly with the 
log SI of OMP-stimulated mediastinal 
lymph node cells (data not shown). 
DISCUSSION 
The results reported here indicate 
that lymphocytes from calves exposed 
to live P. haemolytica react to frac-
tionated antigens of P. haemolytica 
and a whole cell sonicate by undergo-
ing mitosis and producing -y-inter-
feron. These responses are indications 
that the calves have developed cell-
mediated immunity to P. haemolytica. 
The lymphocyte responses were 
detected in lymph node lymphocytes 
collected 4 or 5 d after intratracheal 
challenge with P. haemolytica in 
calves that had been exposed to viru-
lent P. haemolytica 31 d before chal-
lenge, with no evidence of responses 
in calves that had not been previously 
exposed. Previous vaccination with 
2 doses of a killed alum adjuvanted 
vaccine also gave indications of stim-
ulating lymphocyte proliferation and 
-y-interferon production, but the 
response was lower and was not sta-
tistically significant. 
The lymphocyte responsiveness to 
P. haemolytica antigens was found 
only in lymph node lymphocytes col-
lected at necropsy and not in PBMC 
collected prior to intratracheal chal-
lenge on day 31 . Peripheral blood 
mononuclear cells were not tested on 
the day of necropsy because sufficient 
personnel weren't available to test 
both lymph node and blood lympho-
cytes at the same time. The results 
indicate that either the lymphocytes 
from the blood do not develop 
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Figure 4. Correlation of proliferative (A), 
'Y-interferon (8), or antileukotoxin antibody 
(C) response with % pneumonia of calves 
after challenge exposure to P. haemolytica 
31 d after calves were vaccinated or infected 
with P. haemolytica. Antibody titers 25 d 
after vaccination or infection were deter-
mined by a toxin neutralization assay. The 
proliferative values represent stimulation 
index (SI), the quotient of CPM of P. 
haemolytica OMP-stimulated cells and back-
ground wells. IFN represent the difference of 
ng of 'Y-interferon/mL of P. haemolytica 
OMP-stimulated wells from background 
wells. Different symbols are used to identify 
the treatment group of the individuals. Cor-
relation coefficients (r values) are statisti-
cally significant when P S 0.05. 
detectable reactivity to P. haemolyt-
ica antigens, or that the reactivity is 
not detectable until after challenge. 
Since the convalescent group had 
recovered from a previous challenge 
and still did not develop detectable 
PBMC reactivity to P. haemolytica 
antigens, it seems more likely that the 
reactive lymphocytes were not present 
in the blood and were partitioned in 
the lymph nodes. It is also possible 
that in the in vitro assays, the antigen 
presenting cells in the lymph nodes 
were more effective than those in the 
peripheral blood. The lymphocyte 
reactivity was detected when four of 
the five P. haemolytica antigen prepa-
rations were used to stimulate the lym-
phocytes in vitro, with the capsular 
polysacccharide being the exception. 
The highest proliferative responses 
for mediastinal lymph node cells 
occurred in calves in the live vaccine 
group and the convalescent group. 
There was clinical evidence of pneu-
monia in all calves of the convales-
cent group and chronic pneumonia 
was present in 2 of 3 calves at 
necropsy. In cattle, the caudal medi-
astinal lymph node receives lymphatic 
flow from the lung (25), therefore 
abundant P. haemolytica antigen from 
pneumonic parenchyma should have 
been received by the caudal mediasti-
nal lymph node of calves in the con-
valescent group. 
Calves in the bacterin group had 
higher proliferative responses in 
superficial cervical than in mediasti-
nal lymph node cells, indicating that 
the immunologic responses were 
localized near the site of administra-
tion of the bacterin. Conversely, 
calves in the live vaccine group had 
higher 'Y-interferon responses (and 
higher, but not statistically significant 
proliferative responses) in mediastinal 
than superficial cervical lymph node 
cells, indicating that abundant antigen 
from P. haemolytica was delivered to 
mediastinal lymph nodes for sensiti-
zation ofT-lymphocytes. It is possi-
ble that the live vaccine replicated in 
the lung or that blood-borne antigens 
were removed in the lung and trans-
ported to mediastinal lymph nodes. 
Pasteurella haemolytica may cause 
pneumonia when inoculated intra-
venously into animals (26,27) and it is 
possible that the live vaccine repli-
cated at sites other than the site of 
vaccination. Administration of live 
P. haemolytica vaccine has been 
associated with P. haemolytica sep-
ticemia and meningitis in cattle (28). 
In the present study, calves vacci-
nated with the live vaccine had febrile 
responses after vaccination, as well as 
extensive tissue swelling at the site of 
vaccination; either may be associated 
with septicemia, but blood cultures 
were not performed on calves to 
determine if bacteremia occurred. 
The titer of antileukotoxin antibody 
in the serum on day 25 correlated sig-
nificantly with protection from chal-
lenge, whereas the lymphocyte prolif-
eration and 'Y-interferon production 
did not correlate with protection. This 
again confirms the important role of 
antileukotoxin antibody in protecting 
cattle from pneumonia caused by P. 
haemolytica. 'Y-interferon is known to 
activate neutrophils from cattle to 
have enhanced bactericidal activity 
(29). Even though there was no signif-
icant correlation between either lym-
phocyte proliferation or 'Y-interferon 
production, and extent of pneumonia 
after challenge, it is still possible that 
CMI may contribute to protection of 
cattle from P. haemolytica induced 
pneumonia. Further studies will be 
needed to determine the importance of 
the observation that lymph node lym-
phocytes from cattle exposed to live 
P. haemolytica respond to P. hae-
molytica antigens by proliferating and 
secreting 'Y- interferon. 
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